Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Noradrenaline metabolites

Decreased urinary excretion of the main central noradrenaline metabolite MHPG ( )... [Pg.158]

Increased sensitivity to stress may be related to spontaneous recurrence of metamfetamine psychosis, triggering flashbacks. Stressful experiences, together with metamfetamine use, induce sensitization to stress associated with noradrenergic hyperactivity, involving increased dopamine release (54,55). This hypothesis has been investigated by determining plasma noradrenaline metabolite... [Pg.185]

Determination of 3-Methoxy-4-hydroxy-phenylethylene Glycol, a Noradrenaline Metabolite, in Cerebrospinal Fluid and Urine... [Pg.194]

Figure 8.8 The metabolic pathway(s) for noradrenaline. MAO is responsible for the oxidative deamination of noradrenaline derivatives while COMT 0-methylates noradrenaline. Most intraneuronal metabolism involves MAO while COMT is mainly found extraneuronally. However, both these enz5unes can act on each other s products, yielding a complex cocktail of metabolites. The reasons for this complex network of metabolites are not known... Figure 8.8 The metabolic pathway(s) for noradrenaline. MAO is responsible for the oxidative deamination of noradrenaline derivatives while COMT 0-methylates noradrenaline. Most intraneuronal metabolism involves MAO while COMT is mainly found extraneuronally. However, both these enz5unes can act on each other s products, yielding a complex cocktail of metabolites. The reasons for this complex network of metabolites are not known...
One of these compounds, venlafaxine (licensed in the UK in 1996), is regarded as an inhibitor of both 5-HT and noradrenaline reuptake but this is based on its actions in vitro. At low doses in vivo, it is a more potent inhibitor of 5-HT (Ki 39 nM) than noradrenaline reuptake (K 210 nM). Moreover, its active metabolite, O-demethylven-lafaxine, is a weaker inhibitor of NA reuptake, and has a longer half-life, than its parent compound. However, at high doses, venlafaxine inhibits reuptake of both these monoamines but has negligible activity at muscarinic, Hi-receptors or ai-adrenoceptors and... [Pg.441]

Inside the cytoplasm of the presynaptic neuron the monoamines are exposed to the mitochondrial outer membrane-bound enzyme monoamine oxidase (MAO). MAO breaks the monoamines down into inactive metabolites before they are taken up into the vesicles. However, if MAO is inhibited, then the monoamines enter the vesicles and are available for release. MAO inhibitors, such as moclobemide, have been used in the treatment of depression, since they increase the availability of noradrenaline and serotonin. Selegiline is used for Parkinson s disease, since it raises dopamine levels. [Pg.34]

Desipramine An active metabolite of imipramine that is more selective for inhibiting noradrenaline reuptake into the presynaptic neuron. [Pg.241]

Disulfoton exposure altered catecholamine levels in animals, and this hormonal imbalance may be associated with elevated acetylcholine levels (Brzezinski 1969, 1972, 1973 Brzezinski and Ludwicki 1973 Brzezinski and Rusiecki 1970 Wysocka-Paruszewska 1970, 1971). In these studies, acute dosing with disulfoton caused increases in urinary and plasma noradrenaline and adrenaline levels, accompanied by decreases of adrenaline in the adrenal glands, in rats. In addition, the major urinary metabolite of catecholamine metabolism, 4-hydroxy-3-methoxymandelic acid (HMMA), was recovered in the urine from rats given acute doses of disulfoton (Wysocka-Paruszewska 1970,... [Pg.73]

Urine catecholamines may also serve as biomarkers of disulfoton exposure. No human data are available to support this, but limited animal data provide some evidence of this. Disulfoton exposure caused a 173% and 313% increase in urinary noradrenaline and adrenaline levels in female rats, respectively, within 72 hours of exposure (Brzezinski 1969). The major metabolite of catecholamine metabolism, HMMA, was also detected in the urine from rats given acute doses of disulfoton (Wysocka-Paruszewska 1971). Because organophosphates other than disulfoton can cause an accumulation of acetylcholine at nerve synapses, these chemical compounds may also cause a release of catecholamines from the adrenals and the nervous system. In addition, increased blood and urine catecholamines can be associated with overstimulation of the adrenal medulla and/or the sympathetic neurons by excitement/stress or sympathomimetic drugs, and other chemical compounds such as reserpine, carbon tetrachloride, carbon disulfide, DDT, and monoamine oxidase inhibitors (MAO) inhibitors (Brzezinski 1969). For these reasons, a change in catecholamine levels is not a specific indicator of disulfoton exposure. [Pg.122]

Increased levels of urinary catecholamines may also be associated with accumulation of acetylcholine that resulted from acetylcholinesterase inhibition by disulfoton. No human data were located to support this, but limited animal data provide some evidence. Disulfoton exposure caused a 173% and 313% increase in urinary noradrenaline and adrenaline levels in rats, respectively, within 72 hours (Brzezinski 1969). The major metabolite of catecholamine metabolism, HMMA, was also detected in the urine from rats given acute doses of disulfoton (Wysocka-Paruszewska 1971). [Pg.123]

HT) into the nerve terminal, the desmethylated metabolites show selectivity as noradrenaline uptake inhibitors. Thus no TCA can be considered to be selective in inhibiting the uptake of either of these biogenic amines. In the case of TCA overdose, the normal oxidative pathways in the liver are probably saturated, which leads to a disproportionately high concentration of the desmethylated metabolite. The practical consequence of this finding is that toxic plasma concentrations of a TCA are very likely to occur if the dose of the drug is increased in those patients who fail to respond to normal therapeutic doses of the drug. Such a transition to toxic doses could occur suddenly. [Pg.83]

The role of serotonin (5-hydroxytryptamine, 5-HT) has also been extensively studied in depressed patients. Whereas the overall psycho-physiological effects of noradrenaline in the CNS appear to be linked to drive and motivation, 5-HT is primarily involved in the expression of mood. It is not surprising therefore to find that the serotonergic system is abnormal in depression. This is indicated by a reduction in the main 5-HT metabolite, 5-hydroxy indole acetic acid (5-HIAA), in the cerebrospinal fluid of severely depressed patients and a reduction in 5-HT and 5-HIAA in the limbic regions of the brain of suicide victims. The 5-HT receptor function also appears to be abnormal in depression. This is indicated by an increase in the density of cortical 5-HT2a receptors in the brains of suicide victims and also on the platelet membrane of depressed patients. Platelets may be considered as accessible models of the nerve terminal. [Pg.157]

Lastly, nomifensine was an interesting antidepressant that also had noradrenaline, dopamine and, due to its 4-hydroxy metabolite, serotonin reuptake properties. It was withdrawn some years ago because of the occurrence of haemolytic anaemia in a small number of patients. It was a particularly effective drug in the treatment of depression in patients with epilepsy as, unlike many antidepressants available at that time, it did not affect the seizure threshold. [Pg.176]

The mechanism of deprenyl s action is unclear. In addition to enhancing dopaminergic activity in the brain by inhibiting dopamine degradation, deprenyl is metabolized into various stimulant metabolites. In spontaneously hyperactive rats used in an animal model of ADHD, chronic deprenyl administration improved im-pulsivity (but not hyperactivity or attention) along with altering levels of noradrenaline, dopamine, and serotonin and their metabolites (Boix et ah, 1998). [Pg.537]

As outlined previously, initial biological hypotheses of mood disorders were derived from the pharmacological actions of antidepressant drugs, which increase synaptic concentrations of noradrenaline (NA] and/or serotonin. Consequently, the biogenic amine hypothesis was formulated, but it lacks consistent proof that NA and/or serotonin release is indeed diminished. This failure is in part a result of the limited access to relevant brain areas. Measurements of NA and serotonin and their metabolites in blood, urine, and CSF... [Pg.24]

Baker GB, Reynolds GP Biogenic amines and their metabolites in Alzheimer s disease noradrenaline, 5-hydroxytryptamine and 5-hydroxy indole-3-acetic acid depleted in hippocampus but not in substantia innominata. Neurosci Lett 100 335-339, 1989... [Pg.590]


See other pages where Noradrenaline metabolites is mentioned: [Pg.411]    [Pg.891]    [Pg.891]    [Pg.183]    [Pg.194]    [Pg.183]    [Pg.14]    [Pg.459]    [Pg.82]    [Pg.83]    [Pg.3496]    [Pg.21]    [Pg.194]    [Pg.411]    [Pg.891]    [Pg.891]    [Pg.183]    [Pg.194]    [Pg.183]    [Pg.14]    [Pg.459]    [Pg.82]    [Pg.83]    [Pg.3496]    [Pg.21]    [Pg.194]    [Pg.356]    [Pg.1184]    [Pg.98]    [Pg.84]    [Pg.440]    [Pg.32]    [Pg.20]    [Pg.31]    [Pg.160]    [Pg.524]    [Pg.107]    [Pg.73]    [Pg.196]    [Pg.188]    [Pg.87]    [Pg.320]    [Pg.259]    [Pg.526]    [Pg.398]    [Pg.257]    [Pg.345]   
See also in sourсe #XX -- [ Pg.224 ]




SEARCH



© 2024 chempedia.info